3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
12
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Interventions
Prednisone
5
Docetaxel
4
niraparib
2
enzalutamide
2
darolutamide
2
Pluvicto
2
Abiraterone Acetate
2
olaparib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pioglitazone
1
Omeprazole
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
olaparib
×
90 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled